Project Grant W81XWH2110041

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance a novel gene therapy approach as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The primary product to be developed and validated under this $1,193,262 award is an adeno-associated virus (AAV)-mediated gene therapy that targets the SGPL1 gene, which encodes an enzyme that regulates the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the assessment of a peptide-based therapy for treating lung fibrosis, a common and serious condition associated with systemic sclerosis. The $389,754 award to Thendor Therapeutics LLC will fund in vivo studies evaluating the therapeutic potential of the peptide in a murine model of lung fibrosis....

This $286,739 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Fibronox, L.L.C., a woman-owned small business. The project aims to assess the clinical translatability of inhaled Nrf2 activator therapy for idiopathic pulmonary fibrosis (IPF), a devastating age-related fibrotic disease with limited treatment options. Specifically, the work will evaluate the efficacy of three FDA-approved...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this 17-month grant, with an end date of February 28, 2025, is to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. Novomedix has developed a series of small molecule compounds that inhibit...

The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $548,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oncoarendi Therapeutics LLC. The grant's objective is to develop a novel, disease-modifying oral medication for idiopathic pulmonary fibrosis (IPF) that targets the myocardin-related transcription factor (MRTF) pathway. The key goals of this Phase I project are to optimize a lead compound...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $695,403 award supports research to develop novel therapeutic approaches for treating pulmonary fibrosis by targeting dysfunctions in pulmonary endothelial cells. The central hypothesis is that restoring microvasculature integrity through nanoparticle gene therapy or cell...

This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $596,179 in funding to Baylor College of Medicine to study the role of macropinocytosis in lung fibrosis. The 5-year research project aims to determine whether inhibiting macropinocytosis, a cellular process involved in nutrient uptake, can attenuate pulmonary fibrosis in animal models and cell culture systems. The project will also...

The University of Pittsburgh has been awarded a $325,950 project grant from the National Institute on Aging's Aging Research program (CFDA 93.866) to conduct research on preventing pulmonary fibrosis. The research aims to establish that the tyrosine kinase protein FGR, which is induced in senescent lung cells, initiates pulmonary fibrosis by secreting proinflammatory proteins and recruiting inflammatory cells. The project will use mouse models to confirm the role of FGR in pulmonary fibrosis and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $805,845 to the Proteogenomics Research Institute for Systems Medicine to develop and test a novel lung precision drug delivery system (LPDDS) targeting lung myofibroblasts. The goal is to actively transport anti-fibrotic therapies directly into lung tissue to comprehensively block activation and differentiation of myofibroblasts,...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $774,585 in funding to The Regents of the University of California, San Francisco (UCSF) from July 15, 2024 to June 30, 2028. The grant supports research to investigate the mechanisms underlying the emergence and function of inflammatory fibroblasts in pulmonary fibrosis. The research aims to elucidate how inflammatory fibroblasts...